Medical management of hepatorenal syndrome
Andrew Davenport, Jawad Ahmad, Ali Al-Khafaji, John A Kellum, Yuri S Genyk, Mitra K Nadim
Nephrology, Dialysis, Transplantation 2012, 27 (1): 34-41
22287700
Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However, understanding the pathogenesis of HRS has led to the introduction of treatments designed to increase renal perfusion and mean arterial blood pressure using vasopressors and albumin, which has led to improvement in renal function in ∼50% of patients.
Related Papers
Make the most of Read.
Download the mobile app.
Download the mobile app.
Responses
Raúl Valdés
The paper mentions albumin at 1 gr/kg, up to 100 gr a day for one day, then describes the same dosage for two days in a row. Which one is the better one?
Posted 15 Oct, 2014 at 23:52Omar Soler
Any further info on paracentesis, how much and when tomstop, also related with albumin administration.
Posted 4 Jun, 2014 at 0:59Nice paper!
Hass Beeb
Excellent review
Posted 21 Mar, 2014 at 12:06Tito Freire
Excellent review thanks you
Posted 7 Oct, 2015 at 8:22Alejo Ramírez
Good review, congratulaciones
Posted 27 Mar, 2015 at 11:51Agus Sudiro Waspodo
Interesting
Posted 2 Sep, 2019 at 12:32Bizimana Jean Baptiste
Good interesting
Posted 9 Dec, 2018 at 10:45Roilan Garcia
Exellent update.
Posted 9 Jan, 2015 at 16:54Saqib Musharaf
A good study.
Posted 19 Apr, 2015 at 18:39Shreya Saxena
I m not able to open can someone help
Posted 21 Dec, 2020 at 6:28Abdullah Asiri
Nice
Posted 19 Apr, 2017 at 23:33lorena teresita
Good
Posted 26 Sep, 2016 at 23:44FABIANA contieri
Very Nice review!
Posted 25 Mar, 2016 at 20:12Dr.Abhinav Choudhury
Helpful
Posted 23 Nov, 2015 at 6:13Kayak Masajes
Interesante
Posted 24 Apr, 2015 at 23:25William Rutherford
Patients with HRS
Posted 18 Feb, 2021 at 9:40should be optimally resuscitated, with intravenous administra-
tion of albumin (initially 1 g of albumin/kg of body weight, up
to a maximum of 100 g, followed by 20–40 g/day) in combi-
nation with vasopressor therapy (1A), for up to 14 days (2D)